{
  "fullName": "Robert Edwards",
  "slug": "robert-edwards",
  "title": "MD",
  "specialty": "Reproductive Medicine",
  "geography": {
    "country": "Global",
    "city": "Unknown",
    "region": "Unknown"
  },
  "status": "LIVING",
  "tier": "UNRANKED",
  "rankingScore": 28,
  "hIndex": 106,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "Nobel Prize in Physiology or Medicine. Associated with University of Cambridge.",
  "aiSummary": "Robert Edwards is a reproductive medicine specialist with an H-index of 106 at University of Cambridge (Member). Has been published in The Lancet, New England Journal of Medicine, The Lancet Oncology. Based in Unknown, Unknown, Global.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [
    "University of Cambridge"
  ],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "University of Cambridge",
      "role": "Member",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "Reproductive Medicine"
  ],
  "knowsAbout": [
    "Nobel Prize in Physiology or Medicine"
  ],
  "citations": [
    {
      "title": "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial",
      "journal": "The Lancet",
      "year": 2010,
      "citationCount": 7146,
      "doi": "10.1016/s0140-6736(10)61121-x",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(10)61121-x",
      "verified": true
    },
    {
      "title": "Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors",
      "journal": "New England Journal of Medicine",
      "year": 2011,
      "citationCount": 2512,
      "doi": "10.1056/nejmoa1003825",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1003825",
      "verified": true
    },
    {
      "title": "Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study",
      "journal": "The Lancet Oncology",
      "year": 2020,
      "citationCount": 2383,
      "doi": "10.1016/s1470-2045(20)30445-9",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(20)30445-9",
      "verified": true
    },
    {
      "title": "Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer",
      "journal": "New England Journal of Medicine",
      "year": 2014,
      "citationCount": 1969,
      "doi": "10.1056/nejmoa1406766",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1406766",
      "verified": true
    },
    {
      "title": "Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer",
      "journal": "JAMA Oncology",
      "year": 2018,
      "citationCount": 1774,
      "doi": "10.1001/jamaoncol.2018.0013",
      "sourceUrl": "https://doi.org/10.1001/jamaoncol.2018.0013",
      "verified": true
    },
    {
      "title": "Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial",
      "journal": "The Lancet",
      "year": 2012,
      "citationCount": 1686,
      "doi": "10.1016/s0140-6736(11)61873-4",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(11)61873-4",
      "verified": true
    },
    {
      "title": "KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors",
      "journal": "New England Journal of Medicine",
      "year": 2020,
      "citationCount": 1620,
      "doi": "10.1056/nejmoa1917239",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1917239",
      "verified": true
    },
    {
      "title": "Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial",
      "journal": "The Lancet",
      "year": 2018,
      "citationCount": 1286,
      "doi": "10.1016/s0140-6736(18)31257-1",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(18)31257-1",
      "verified": true
    },
    {
      "title": "Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study",
      "journal": "The Lancet Oncology",
      "year": 2012,
      "citationCount": 1258,
      "doi": "10.1016/s1470-2045(12)70344-3",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(12)70344-3",
      "verified": true
    },
    {
      "title": "Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer",
      "journal": "New England Journal of Medicine",
      "year": 2020,
      "citationCount": 1212,
      "doi": "10.1056/nejmoa2004413",
      "sourceUrl": "https://doi.org/10.1056/nejmoa2004413",
      "verified": true
    },
    {
      "title": "Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial",
      "journal": "The Lancet Oncology",
      "year": 2016,
      "citationCount": 1101,
      "doi": "10.1016/s1470-2045(16)00175-3",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(16)00175-3",
      "verified": true
    },
    {
      "title": "Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer",
      "journal": "JAMA Oncology",
      "year": 2020,
      "citationCount": 1072,
      "doi": "10.1001/jamaoncol.2020.3370",
      "sourceUrl": "https://doi.org/10.1001/jamaoncol.2020.3370",
      "verified": true
    },
    {
      "title": "Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial",
      "journal": "The Lancet Oncology",
      "year": 2014,
      "citationCount": 1045,
      "doi": "10.1016/s1470-2045(14)70473-5",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(14)70473-5",
      "verified": true
    },
    {
      "title": "HER2-targeted therapies — a role beyond breast cancer",
      "journal": "Nature Reviews Clinical Oncology",
      "year": 2019,
      "citationCount": 1012,
      "doi": "10.1038/s41571-019-0268-3",
      "sourceUrl": "https://doi.org/10.1038/s41571-019-0268-3",
      "verified": true
    },
    {
      "title": "T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028",
      "journal": "Journal of Clinical Oncology",
      "year": 2018,
      "citationCount": 960,
      "doi": "10.1200/jco.2018.78.2276",
      "sourceUrl": "https://doi.org/10.1200/jco.2018.78.2276",
      "verified": true
    },
    {
      "title": "Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis",
      "journal": "The Lancet Oncology",
      "year": 2011,
      "citationCount": 880,
      "doi": "10.1016/s1470-2045(11)70232-7",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(11)70232-7",
      "verified": true
    },
    {
      "title": "Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies",
      "journal": "Clinical Cancer Research",
      "year": 2004,
      "citationCount": 796,
      "doi": "10.1158/1078-0432.ccr-03-0655",
      "sourceUrl": "https://doi.org/10.1158/1078-0432.ccr-03-0655",
      "verified": true
    },
    {
      "title": "Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib",
      "journal": "Journal of Clinical Oncology",
      "year": 2005,
      "citationCount": 775,
      "doi": "10.1200/jco.2005.01.388",
      "sourceUrl": "https://doi.org/10.1200/jco.2005.01.388",
      "verified": true
    },
    {
      "title": "Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial",
      "journal": "The Lancet Oncology",
      "year": 2016,
      "citationCount": 685,
      "doi": "10.1016/s1470-2045(15)00553-7",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(15)00553-7",
      "verified": true
    },
    {
      "title": "Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial",
      "journal": "Journal of Clinical Oncology",
      "year": 2015,
      "citationCount": 611,
      "doi": "10.1200/jco.2015.62.6598",
      "sourceUrl": "https://doi.org/10.1200/jco.2015.62.6598",
      "verified": true
    },
    {
      "title": "Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study",
      "journal": "Journal of Clinical Oncology",
      "year": 2014,
      "citationCount": 611,
      "doi": "10.1200/jco.2013.53.6136",
      "sourceUrl": "https://doi.org/10.1200/jco.2013.53.6136",
      "verified": true
    },
    {
      "title": "Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial",
      "journal": "The Lancet",
      "year": 2023,
      "citationCount": 601,
      "doi": "10.1016/s0140-6736(23)00620-7",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(23)00620-7",
      "verified": true
    },
    {
      "title": "HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer",
      "journal": "Gastric Cancer",
      "year": 2014,
      "citationCount": 588,
      "doi": "10.1007/s10120-014-0402-y",
      "sourceUrl": "https://doi.org/10.1007/s10120-014-0402-y",
      "verified": true
    },
    {
      "title": "Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001",
      "journal": "Annals of Oncology",
      "year": 2019,
      "citationCount": 557,
      "doi": "10.1093/annonc/mdz131",
      "sourceUrl": "https://doi.org/10.1093/annonc/mdz131",
      "verified": true
    },
    {
      "title": "Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study",
      "journal": "Journal of Clinical Oncology",
      "year": 2017,
      "citationCount": 503,
      "doi": "10.1200/jco.2017.72.5952",
      "sourceUrl": "https://doi.org/10.1200/jco.2017.72.5952",
      "verified": true
    },
    {
      "title": "Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study",
      "journal": "Journal of Clinical Oncology",
      "year": 2013,
      "citationCount": 487,
      "doi": "10.1200/jco.2012.48.3552",
      "sourceUrl": "https://doi.org/10.1200/jco.2012.48.3552",
      "verified": true
    },
    {
      "title": "Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial",
      "journal": "Nature Medicine",
      "year": 2023,
      "citationCount": 445,
      "doi": "10.1038/s41591-023-02465-7",
      "sourceUrl": "https://doi.org/10.1038/s41591-023-02465-7",
      "verified": true
    },
    {
      "title": "Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification",
      "journal": "Journal of Thoracic Oncology",
      "year": 2011,
      "citationCount": 433,
      "doi": "10.1097/jto.0b013e31821528d3",
      "sourceUrl": "https://doi.org/10.1097/jto.0b013e31821528d3",
      "verified": true
    },
    {
      "title": "Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta.",
      "journal": "Proceedings of the National Academy of Sciences",
      "year": 1994,
      "citationCount": 425,
      "doi": "10.1073/pnas.91.19.8772",
      "sourceUrl": "https://doi.org/10.1073/pnas.91.19.8772",
      "verified": true
    },
    {
      "title": "<i>MET</i> Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib",
      "journal": "Journal of Clinical Oncology",
      "year": 2011,
      "citationCount": 419,
      "doi": "10.1200/jco.2011.35.4928",
      "sourceUrl": "https://doi.org/10.1200/jco.2011.35.4928",
      "verified": true
    },
    {
      "title": "Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials",
      "journal": "JAMA Oncology",
      "year": 2021,
      "citationCount": 415,
      "doi": "10.1001/jamaoncol.2021.0275",
      "sourceUrl": "https://doi.org/10.1001/jamaoncol.2021.0275",
      "verified": true
    },
    {
      "title": "Inhibition of Histone Deacetylation Blocks Cardiac Hypertrophy Induced by Angiotensin II Infusion and Aortic Banding",
      "journal": "Circulation",
      "year": 2005,
      "citationCount": 363,
      "doi": "10.1161/circulationaha.105.559724",
      "sourceUrl": "https://doi.org/10.1161/circulationaha.105.559724",
      "verified": true
    },
    {
      "title": "Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma",
      "journal": "JAMA Oncology",
      "year": 2016,
      "citationCount": 292,
      "doi": "10.1001/jamaoncol.2016.5580",
      "sourceUrl": "https://doi.org/10.1001/jamaoncol.2016.5580",
      "verified": true
    },
    {
      "title": "Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer",
      "journal": "Journal of Clinical Oncology",
      "year": 2015,
      "citationCount": 289,
      "doi": "10.1200/jco.2014.60.0320",
      "sourceUrl": "https://doi.org/10.1200/jco.2014.60.0320",
      "verified": true
    },
    {
      "title": "Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study",
      "journal": "The Lancet Oncology",
      "year": 2023,
      "citationCount": 287,
      "doi": "10.1016/s1470-2045(23)00541-7",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(23)00541-7",
      "verified": true
    },
    {
      "title": "Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial",
      "journal": "The Lancet Oncology",
      "year": 2017,
      "citationCount": 286,
      "doi": "10.1016/s1470-2045(17)30682-4",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(17)30682-4",
      "verified": true
    },
    {
      "title": "Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors",
      "journal": "Clinical Cancer Research",
      "year": 2019,
      "citationCount": 281,
      "doi": "10.1158/1078-0432.ccr-18-2740",
      "sourceUrl": "https://doi.org/10.1158/1078-0432.ccr-18-2740",
      "verified": true
    },
    {
      "title": "Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer",
      "journal": "Journal of Clinical Oncology",
      "year": 2022,
      "citationCount": 261,
      "doi": "10.1200/jco.21.02010",
      "sourceUrl": "https://doi.org/10.1200/jco.21.02010",
      "verified": true
    },
    {
      "title": "Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation",
      "journal": "Clinical Cancer Research",
      "year": 2006,
      "citationCount": 256,
      "doi": "10.1158/1078-0432.ccr-05-2845",
      "sourceUrl": "https://doi.org/10.1158/1078-0432.ccr-05-2845",
      "verified": true
    },
    {
      "title": "Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial",
      "journal": "Nature Medicine",
      "year": 2023,
      "citationCount": 249,
      "doi": "10.1038/s41591-023-02321-8",
      "sourceUrl": "https://doi.org/10.1038/s41591-023-02321-8",
      "verified": true
    },
    {
      "title": "Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP.",
      "journal": "Proceedings of the National Academy of Sciences",
      "year": 1994,
      "citationCount": 246,
      "doi": "10.1073/pnas.91.12.5330",
      "sourceUrl": "https://doi.org/10.1073/pnas.91.12.5330",
      "verified": true
    },
    {
      "title": "Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study",
      "journal": "Gastric Cancer",
      "year": 2019,
      "citationCount": 242,
      "doi": "10.1007/s10120-018-00909-5",
      "sourceUrl": "https://doi.org/10.1007/s10120-018-00909-5",
      "verified": true
    },
    {
      "title": "Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial",
      "journal": "Journal of Clinical Oncology",
      "year": 2016,
      "citationCount": 238,
      "doi": "10.1200/jco.2015.65.1901",
      "sourceUrl": "https://doi.org/10.1200/jco.2015.65.1901",
      "verified": true
    },
    {
      "title": "Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index",
      "journal": "PLoS ONE",
      "year": 2015,
      "citationCount": 236,
      "doi": "10.1371/journal.pone.0139749",
      "sourceUrl": "https://doi.org/10.1371/journal.pone.0139749",
      "verified": true
    },
    {
      "title": "Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis",
      "journal": "Breast Cancer Research",
      "year": 2011,
      "citationCount": 233,
      "doi": "10.1186/bcr2834",
      "sourceUrl": "https://doi.org/10.1186/bcr2834",
      "verified": true
    },
    {
      "title": "First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors",
      "journal": "Annals of Oncology",
      "year": 2017,
      "citationCount": 224,
      "doi": "10.1093/annonc/mdx002",
      "sourceUrl": "https://doi.org/10.1093/annonc/mdx002",
      "verified": true
    },
    {
      "title": "Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma",
      "journal": "Laboratory Investigation",
      "year": 2004,
      "citationCount": 211,
      "doi": "10.1038/labinvest.3700060",
      "sourceUrl": "https://doi.org/10.1038/labinvest.3700060",
      "verified": true
    },
    {
      "title": "Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100",
      "journal": "Journal of Clinical Oncology",
      "year": 2020,
      "citationCount": 211,
      "doi": "10.1200/jco.20.00892",
      "sourceUrl": "https://doi.org/10.1200/jco.20.00892",
      "verified": true
    },
    {
      "title": "Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)",
      "journal": "Journal of Clinical Oncology",
      "year": 2009,
      "citationCount": 204,
      "doi": "10.1200/jco.2009.27.15_suppl.lba4509",
      "sourceUrl": "https://doi.org/10.1200/jco.2009.27.15_suppl.lba4509",
      "verified": true
    },
    {
      "title": "Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066",
      "journal": "Journal of Clinical Oncology",
      "year": 2009,
      "citationCount": 202,
      "doi": "10.1200/jco.2009.27.15_suppl.3509",
      "sourceUrl": "https://doi.org/10.1200/jco.2009.27.15_suppl.3509",
      "verified": true
    }
  ],
  "awards": [],
  "timeline": [],
  "openalexId": "https://openalex.org/A5050684671"
}